Open AccessThe first 10 years’ experience in radical retropubic prostatectomy: Complications, lower urinary tract symptoms, and quality of life - a single-center experience
Author(s) -
Ljubomir Dinić,
Dragoslav Bašić,
Ivan Ignjatović,
Vesna Dinić,
Natalija Vuković,
Mlađjan Golubović,
Miodrag Djordjević,
Darko Laketić,
Andrej Veljković
Publication year - 2021
Publication title -
srpski arhiv za celokupno lekarstvo
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.135
H-Index - 17
eISSN - 2406-0895
pISSN - 0370-8179
DOI - 10.2298/sarh210211073d
Subject(s) - medicine , international prostate symptom score , lower urinary tract symptoms , quality of life (healthcare) , radical retropubic prostatectomy , incidence (geometry) , prostate cancer , urology , prostatectomy , urinary system , urinary incontinence , surgery , prostate , cancer , physics , nursing , optics
/Objective. This 10-year prospective study?s primary objective was to evaluate the incidence of complications of radical retropubic prostatectomy (RRP). The secondary objective was to analyze how RRP affects lower urinary tract symptoms (LUTS) and quality of life (QoL) by using the International Prostate Symptom Score (IPSS). Methods. We analyzed 254 patients who underwent RRP in the period 2009?2018. All complications were graded according to the Clavien?Dindo classification. To assess urinary symptoms and the QoL, all the examinees filled out the IPSS and the International Prostate Symptom Score for QoL (IPSS QoL) questionnaires during preoperative preparation and three, six, and 12 months after surgery. Results. The incidence of complications Clavien?Dindo grade ? II and grade ? III were 26.4% and 16.5%, respectively. The mean overall IPSS for the entire group of patients after 12 months of follow-up was significantly different from the preoperative baseline value (p < 0.001). Patients with preoperative moderate (IPSS 8?19) and severe urinary symptoms (IPSS 20+) had a statistically significant reduction of urinary symptoms after RRP (p < 0.001). After 12 months, IPSS QoL was statistically significantly lower than the preoperative one (p < 0.05). Conclusion. For patients with clinically localized prostate cancer, RRP is a safe and effective treatment option. It is associated with a higher rate of complications from the Clavien?Dindo grade ? II group. RRP has clinically beneficial effects on LUTS in patients with moderate and severe urinary symptoms and the QoL related to LUTS.